clinical trial · NCT07224373
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca·phase1·recruiting·n = 24
Multiple SclerosisAZD0120 - Regimen 1AZD0120 - Regimen 2
brief summary
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
started
Dec 9, 2025
primary completion
Dec 7, 2028
completion
Dec 7, 2028
last updated
Apr 22, 2026
detailed description
This study will evaluate AZD0120 for safety, including DLTs and TEAEs, by the SRC for determination of the Recommended Phase 2 dose for each disease cohort. Approximately 9-12 participants will be evaluated per disease cohort.
official title
A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol